New York Injury News

FDA orders Botox makers place boxed high injury warning label – New York product injury Alert!

FDA issues healthcare professional alert-increased botox injury warning label.

New York, NY(–The U.S. Food and Drug Administration (FDA) notified healthcare professionals nationwide on Thursday that Botox manufacturers must strengthen product injury warnings. The FDA is requiring licensed manufacturers of botulinum toxin products (Botox) to place a boxed warning label stating the risk of adverse events when using Botox.

The FDA received numerous reports of adverse events and harmful side effects after localized administration of botulinum toxin products. The effects of the toxin spread beyond the injected administration site and injured patients and cosmetic consumers. According to Wikipedia, botulinum toxin also marketed and sold under the brand names; Botox, Dysport, Myobloc, Neurobloc, Xeomin, Botox Cosmetic and Vistabel, is a medication and a neurotoxic protein produced by the bacterium Clostridium botulinum. It is the most toxic protein known. Doctors and nurses throughout the world use botulinum toxin to treat muscle spasms. It is sold commercially for cosmetic treatment. news for New York product injury lawyers.

Exit mobile version